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Abstract
Aim To develop a decision model for the population-level evaluation of strategies to improve the selection of stage II colon 
cancer (CC) patients who benefit from adjuvant chemotherapy.
Methods A Markov cohort model with a one-month cycle length and a lifelong time horizon was developed. Five health 
states were included; diagnosis, 90-day mortality, death other causes, recurrence and CC death. Data from the Netherlands 
Cancer Registry were used to parameterize the model. Transition probabilities were estimated using parametric survival 
models including relevant clinical and pathological covariates. Subsequently, biomarker status was implemented using 
external data. Treatment effect was incorporated using pooled trial data. Model development, data sources used, parameter 
estimation, and internal and external validation are described in detail. To illustrate the use of the model, three example 
strategies were evaluated in which allocation of treatment was based on (A) 100% adherence to the Dutch guidelines, (B) 
observed adherence to guideline recommendations and (C) a biomarker-driven strategy.
Results Overall, the model showed good internal and external validity. Age, tumor growth, tumor sidedness, evaluated lymph 
nodes, and biomarker status were included as covariates. For the example strategies, the model predicted 83, 87 and 77 CC 
deaths after 5 years in a cohort of 1000 patients for strategies A, B and C, respectively.
Conclusion This model can be used to evaluate strategies for the allocation of adjuvant chemotherapy in stage II CC 
patients. In future studies, the model will be used to estimate population-level long-term health gain and cost-effectiveness 
of biomarker-based selection strategies.
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Background
With around 10,500 new cases and 4000 deaths in 2016, 
colon cancer is a major disease in the Netherlands leading 
to a substantial burden for patients, health care and society 
[1]. Over 25% of newly diagnosed colon cancer patients have 
stage II disease and it is likely that this will increase due 
to the recently initiated population-based colorectal cancer 
screening program [2, 3].
In stage II colon cancer, surgical resection is the curative 
treatment option of choice, followed by adjuvant therapy 
in a subgroup of patients. The benefit of adjuvant chemo-
therapy after surgical resection remains a matter of debate. 
Adjuvant chemotherapy is often recommended for stage II 
patients with a high risk of recurrence. However, there is no 
consensus on which factors predict the benefit from adju-
vant chemotherapy. The correct identification of prognostic 
and predictive parameters is essential to optimize survival 
without inducing the harms of overtreatment in patients who 
will not benefit.
Until 2014, high-risk stage II patients were identified 
using clinical and pathological factors, i.e., pT4 stage (i.e., 
tumor growth), < 10 lymph nodes evaluated, perforation, 
vascular invasion, perineural invasion, and a high degree 
of differentiation [4–6]. In response to new findings, the 
Dutch guidelines were updated in 2014 with microsatellite 
stability (MSS) status in addition to the high-risk features 
mentioned above. In 2018, the Dutch association for medical 
oncology (NVMO) indicated that only pT4 and MSS status 
should be considered in the decision to allocate adjuvant 
chemotherapy in stage II colon cancer patients [7–10]. How-
ever, adherence to these guideline recommendations is low. 
In addition to substantiated deviations from the guideline 
recommendations, possible explanations for low adherence 
are unfamiliarity with this guideline, differences in expert 
opinions, and the clinical condition of the patient [11]. Pre-
sumably, increased compliance due to more awareness of 
the guideline recommendations could lead to health gains.
Additional molecular markers may enable improved 
patient selection for adjuvant chemotherapy as a number 
of specific aberrations, such as BRAF and KRAS muta-
tions, are associated with prognosis [12–18]. To illustrate, 
MSI positive stage II and III patients with double wild-type 
cancers had a 5-year cancer-specific survival of 93% (95% 
CI 84–100%); while, patients with cancers harboring muta-
tions in either BRAF or KRAS had a 5-year cancer-specific 
survival of 76% (95% CI 67–85%) [15]. The potential value 
of using these subtypes to inform adjuvant chemotherapy 
selection in colon cancer patients is acknowledged by several 
studies [12, 14].
Despite these developments in the field of colon can-
cer, the cost-effectiveness of different (biomarker-based) 
strategies for selecting high-risk stage II colon cancer 
patients has not been assessed so far. To address this issue, 
we developed the Personalized Adjuvant TreaTment in 
EaRly stage coloN cancer (PATTERN) model to synthesize 
evidence on different aspects of the decision problem, such 
as disease-free survival, overall survival, biomarker status, 
treatment effect, health utilities, and costs, from different 
sources in one coherent framework. This model can be used 
to evaluate the population-level cost-effectiveness of bio-
marker-based selection strategies for high-risk stage II colon 
cancer patients. Model structure, model assumptions, data 
sources, quantification and internal and external validation 
of model predictions are presented in this paper. As an exam-
ple of the application of the model, the NVMO guideline and 
a hypothetical biomarker-driven strategy are compared with 
observed adherence to guideline recommendations based on 
data of the Netherlands cancer registry (NCR).
Methods
Description of the Markov cohort model
The Personalized Adjuvant TreaTment in EaRly stage 
coloN cancer (PATTERN) model is a deterministic Markov 
cohort model that simulates the disease progression of 
stage II colon cancer patients from the moment of diagnosis 
until death. A flowchart of the model is shown in Fig. 1. A 
Markov model describes a sequence of possible events in 
which the probability of a subsequent event depends solely 
on the state currently attained. This means that the time 
spent in a health state or the specific health states that are 
visited has no effect on the probability of a future transition. 
This is commonly referred to as the no-memory property. To 
be able to take time-dependent hazards into account, such 
as the hazards for the transition from recurrence to death, 
we incorporated tunnel states in the Markov model [19]. We 
opted for a cohort approach instead of a micro-simulation 
approach to increase the computational speed, such that the 
probabilistic sensitivity analysis is possible for future cost-
effectiveness analyses. This choice for this approach seems 
counter intuitive for a relatively complex decision model, 
but it was possible by replicating the cohort model for each 
possible subgroup (defined on the basis of the included 
covariates).
We used a 1-month cycle length in the model. The model 
consists of 5 clinical states: diagnosis, 90-day mortality 
(90DM), recurrence, death due to other causes than colon 
cancer (DOC) and death of colon cancer (DCC). All patients 
start in the state ‘diagnosis’, and are treated surgically after 
pathological diagnosis. Furthermore, this state contains the 
option for patients to undergo or not undergo adjuvant chem-
otherapy. From diagnosis, patients may die within 90 days 
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after resection due to complications after surgery or poor 
clinical condition (DIAG-90DM), they may die from DOC 
(DIAG-DOC) or they may develop a recurrence (DIAG-
REC). After transitioning to ‘recurrence’, patients are again 
at risk of DOC (REC-DOC) and DCC (REC-DCC). In the 
model, probabilities for the transitions DIAG-90DM, DIAG-
DOC and DIAG-REC were considered as competing events.
Data used for parameter estimation
Model quantification was based on data from the NCR. 
Recurrence follow-up data are not collected by default in 
the NCR. Therefore, we used a selection of 2271 patients 
from the nationwide registry for which this information was 
collected. The dataset consists of patients diagnosed with 
stage II colon cancer between 2002 and 2008. Patient and 
tumor characteristics, time to recurrence and time to death 
were collected. To estimate transition parameters using this 
dataset, we defined two partly overlapping subpopulations; 
(1) patients who underwent surgery and did not receive 
adjuvant chemotherapy, with or without a recurrence in the 
follow-up (n = 2152) and (2) patients who underwent surgery 
and developed a recurrence, with or without prior adjuvant 
chemotherapy (n = 317) (Fig. 2).
Biomarker data were not collected in the NCR; therefore, 
we used data of three external cohorts to include biomarker 
status. The following three cohorts were used; (1) a cohort 
from the MicroArray and proteomics Technologies to ana-
lyze Colorectal cancer and Hepatic metastases (MATCH) 
study [20], (2) a cohort obtained through the Baylor Scott 
and White Research Institute and Charles A Sammons Can-
cer Center (Texas cohort) [21] and (3) a cohort obtained 
through Instituto Biodonostia, Universidad del País Vasco, 
Centro de Investigación Biomédica en Red de Enfermedades 
Hepaticas y Digestivas (DONOSTIA cohort). These cohorts 
consisted of 105, 133 and 96 stage II colon cancer patients, 
respectively, and provided data on patient and tumor char-
acteristics as well as biomarker status for MSS, BRAF 
(MATCH only) and KRAS (MATCH only).
Parametrization of the model
For DIAG-90DM, we estimated a time-independent transi-
tion probability using the whole NCR population (n = 2271), 
based on the assumption that all observed deaths within 
90 days are due to surgical complications or comorbidi-
ties [22, 23]. For all other transitions, the model was para-
metrized by parametric survival models including relevant 
covariates. The prognostic value of the following covariates 
was tested in our survival models: pT stage, tumor sided-
ness, differentiation grade, number of evaluated lymph nodes 
and age. The covariates were selected based on clinical rel-
evance and data availability.
Transitions DIAG-DOC and DIAG-REC were estimated 
in subpopulation 1, in which patients with adjuvant chemo-
therapy were excluded. Because we aimed to include the 
impact of treatment on recurrence in the model on the basis 
of high-level evidence from randomized trials, we used 
the untreated patients from the NCR to estimate these two 
transitions in the absence of treatment [24]. Transitions 
REC-DOC and REC-DCC were estimated in subpopulation 
2, in which only patients were included who developed a 
recurrence. We assumed that the administration of adjuvant 
chemotherapy after surgery does not influence mortality in 
Fig. 1  Structure of the Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) model
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patients with a recurrence. Therefore, patients treated with 
adjuvant chemotherapy were not excluded in subpopulation 
2.
To estimate the parametric survival models, we tested 
for each transition four commonly used parametric survival 
distributions in health economic modeling (Weibull, Log 
normal, Log logistic and Gompertz) [25]. The choice for a 
distribution was based on the lowest Akaike’s information 
criterion (AIC) in combination with strict visual inspection 
in a model without covariates [25, 26]. After selecting the 
best fitting distribution, the prognostic value of the above-
mentioned covariates was assessed using a forward selection 
procedure. The added covariate was tested for significance 
using the Wald statistic, considering a two-sided p value 
of < 0.157 as statistically significant. Subsequently, the 
variable selection was extensively discussed with clinical 
experts, to ensure a conceptually valid inclusion of covari-
ates. As a final check, the four parametric model distri-
butions were again compared based on the lowest AIC in 
the models including the relevant covariates, which were 
selected in the previous step. This final check was conducted 
to confirm that the distribution selected in step 1 was still the 
best fitting distribution after covariate inclusion. It should be 
noted that the best fitting distribution did not change after 
covariate inclusion for any of the transitions.
In the dataset used for model parametrization, only over-
all survival was reported. That is, no distinction was made 
between DOC and DCC. Making this distinction is neces-
sary to estimate the impact of improved selection strategies 
for adjuvant chemotherapy administration on the number 
of deaths due to colon cancer. To quantify the transition 
REC-DEATH (REC-DOC + REC-DCC), we selected the 
patients who developed a recurrence (subpopulation 2). 
This subpopulation was used to estimate a survival model 
with time to death as the outcome. Subsequently, we dif-
ferentiated between DOC and DCC by assuming that the 
probability of DOC is equal for patients with and without 
a recurrence. That is, we assumed the transition REC-DOC 
to be equal to the transition DIAG-DOC in which DOC was 
estimated in the population without recurrence. The remain-
ing deaths were considered due to DCC. All survival models 
were estimated using the flexsurvreg package in Rstudio ver-
sion 3.4.2 [27].
Addition of biomarker status
Literature shows that MSS, BRAF and KRAS mutation sta-
tus are associated with prognosis in stage II colon cancer 
patients and that these factors may enable improved patient 
selection for adjuvant chemotherapy [12–18]. Therefore, we 
distinguished three biomarker subgroups in the model; (1) 
microsatellite instable tumors (MSI), independent of BRAF 
and KRAS status, (2) microsatellite stable tumors (MSS) 
without a mutation for BRAF or KRAS (MSSdwt), and (3) 
MSS in combination with a mutation in BRAF and/or KRAS 
(MSSmut).
To incorporate biomarker status in the transition DIAG-
REC in the PATTERN model, the survival model reflecting 
time to recurrence since diagnosis was adjusted by includ-
ing a hazard ratio (HR) for each biomarker subgroup. It 
should be noted that we assumed the same effect of bio-
marker status in all subgroups included in the PATTERN 
model. The HR for the MSI subgroup was estimated using 
the MATCH, Texas and Donostia cohorts. The HRs for the 
MSSdwt and MSSmut subgroups were estimated using the 
MATCH cohort only, as in the Texas and Donostia cohorts, 
KRAS and BRAF mutation status was unknown. The HRs 
for the MSSdwt and MSSmut subgroups were estimated 
Fig. 2  Flowchart of the 
2002–2008 NCR data
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relative to the MSI subgroup. The HRs for the biomarker 
subgroups were both estimated in a Gompertz parametric 
survival model and were applied directly to the overall haz-
ard predicted by the Gompertz parametric survival model 
for the transition DIAG-REC, in which the clinical features 
were included.
Addition of treatment effect
The selection strategy determines which patients receive 
adjuvant chemotherapy after diagnosis. The incorporated 
treatment effect was not based on the NCR data due to con-
founding by indication in the dataset. We implemented a 
treatment effect for adjuvant chemotherapy based on a meta-
analysis of 9 Randomized Clinical Trials (RCTs) evaluating 
the effectiveness of adjuvant therapy in stage II colon cancer 
patients, published between 1999 and 2011. An extensive 
description of the used procedure is given elsewhere [24]. 
In short, we systematically searched relevant trials which 
reported summary disease-free survival data. Second, we 
generated patient-level data from the reported summary 
of survival data in the included trials using the method 
described by Hoyle and Henly [28]. Patient-level data of 
4489 patients (events: 853) were generated from seven trials 
which compared fluoropyrimidine monotherapy to no adju-
vant treatment (population 1). Furthermore, patient-level 
data of 1587 patients (events: 341) were generated from 
two trials which compared FOLFOX to fluoropyrimidine 
monotherapy (population 2). In the first population, a HR 
for fluoropyrimidine monotherapy compared to no adjuvant 
treatment of 0.78 (0.68; 0.89) was estimated in a Gompertz 
parametric survival model. In the second population, a HR 
for FOLFOX compared to fluoropyrimidine of 0.94 (0.76; 
1.16) was estimated in a Gompertz model. To calculate a HR 
for FOLFOX compared to no adjuvant chemotherapy, we 
multiplied the HRs estimated in population 1 and 2, which 
resulted in a HR of 0.73. We implemented treatment effect 
in the PATTERN model by adjusting the transition DIAG-
REC. As data on treatment heterogeneity are lacking, poten-
tial differences in treatment effect between subgroups were 
not taken into account.
Competing risk correction
For transitions DIAG-90DM, DIAG-DOC and DIAG-REC, 
parametric survival modeling allowed for the estimation of 
the cause-specific hazard rates, which means that compet-
ing events were treated as censored for the event of interest. 
Because 90DM, DOC and recurrence are mutually exclusive 
events in the Markov cohort model, a competing risk correc-
tion was required. This correction was conducted according 
to the cumulative incidence competing risk (CICR) method 
[29, 30], which has previously been applied in a health eco-
nomic model [31].
In essence, the corrected cumulative risk by time t is an 
estimate of the risk of failure from a specific cause, acknowl-
edging that the absolute risk of the event is lowered by the 
presence of other competing risks. The corrected instantane-
ous risk at time t to experience each one of the transitions 
DIAG-90DM, DIAG-DOC and DIAG-REC is calculated by 
multiplying the hazard to experience each specific event at 
time t multiplied by the cumulative chance to be free of 
any of the three events at t − 1. The competing risk correc-
tion was carried out in discrete time steps of one month, 
corresponding to the 1-monthly cycles used in the Markov 
model. Note that for transitions REC-DOC and REC-DCC, 
a competing risk correction was not necessary, because these 
transitions were estimated jointly in the same survival model 
due to limitations in the data.
Internal validity of the PATTERN model
First, we evaluated the internal validity of the final para-
metric survival models by visual inspection. That is, we 
compared the predicted recurrence and survival rates with 
their 95% confidence intervals to the NCR data. Second, 
the model performance was evaluated with the Green-
wood–D’Agostino–Nam test for model calibration, which 
is a modification of the Hosmer–Lemeshow statistic [32]. 
The test for model calibration was assessed by dividing the 
cohort into deciles based on the predicted risk at 36 months. 
Subsequently, predicted and observed risks were compared. 
Third, the discriminatory capacity of the parametric survival 
models was assessed using the Uno modification of the Har-
rel’s c-statistic, which is suitable for censored survival data 
[33, 34]. Finally, to show that the model simulations corre-
spond well with the NCR data used for model development, 
we compared the model estimates for recurrence and overall 
survival rate with data estimates and the corresponding 95% 
confidence interval at 12, 24, 36, 48 and 60 months. This 
approach was conducted for the overall population, and for 
subgroups for age (< 70 and > 70), pT stage (pT3 and pT4), 
number of lymph nodes examined (< 10 and ≥ 10) and tumor 
sidedness (left and right).
External validation of the PATTERN model
To evaluate the external validity of the PATTERN model, 
model predictions for recurrence and overall survival rate 
were compared to the observed data of the NCR 2015 
cohort, which was not used for model development. The 
NCR 2015 dataset consists of 1214 stage II colon cancer 
patients who did not receive adjuvant treatment for whom 
3-year follow-up data were available for recurrence and over-
all survival (Online Appendix Table 1). Patient subgroups 
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in the model were weighed in accordance with the subgroup 
distribution in the 2015 cohort. The model-predicted num-
ber of recurrences and deaths was compared to the 2015 
data at 12, 24 and 36 months for the overall population and 
subgroups for age (≤ 70 and > 70), pT stage (pT3 and pT4), 
number of lymph nodes examined (≤ 10 and > 10) and tumor 
sidedness (left and right). If the model predictions did not 
fit within the 95% confidence interval of the data for all 3 
evaluated time points for a specific subgroup, the PATTERN 
model was updated by adjusting the regression coefficients 
for that subgroup.
In addition, the implemented treatment effect in the 
PATTERN model, which was based on external RCT data, 
was validated in a separate analysis. First, survival curves 
for recurrence and overall survival were constructed for 
the subset of patients from the 2002–2008 NCR data-
set (n = 129) and the 2015 NCR dataset (n = 115) who 
received adjuvant treatment (Table 1 and Online Appendix 
Table 1). Second, we set up the PATTERN model to simu-
late a scenario in which patients receive adjuvant chemo-
therapy. Note that we weighed the subgroups in the model 
such that it reflected the subgroup distribution in the sys-
temically treated population of cohort 2002–2008 and 
2015. Finally, we visually assessed the agreement between 
the model predictions for recurrence and overall survival 
with the data estimates at 12, 24, 36, 48 and 60 months 
for cohorts 2002–2008 and at 12, 24 and 36 months for 
cohort 2015.
Model‑based predictions for three selection 
strategies
We illustrated the application of our model by evaluating 
the health gain of the following selection strategies: (A) 
100% adherence to the 2018 NVMO guideline, (B) observed 
adherence to NVMO guideline recommendations and (C) 
Table 1  Patient characteristics 
NCR cohort 2002–2008
Data are presented as means (± SD) or numbers (%)
NA not applicable
a This population was used to estimate a time-independent hazard ratio for the transition DIAG-90DM
b Patients who underwent surgery and did not receive adjuvant chemotherapy. This population was used to 
estimate the transitions DIAG-DOC and DIAG-REC
c Patients who underwent surgery and developed a recurrence, independent of adjuvant chemotherapy. This 
population was used to estimate the transition REC-DEATH
d Note that this subpopulation of adjuvant treated patients was only used for external validation of the PAT-
TERN model and not for model parametrization
Variable Whole  populationa 
(n = 2271)
Subpopulation  1b 
(n = 2152)
Subpopulation  2c 
(n = 317)
Adjuvant treated 
 patientsd (n = 129)
Age (years) 70.7 (10.9) 71.5 (10.7) 70.2 (9.4) 61.3 (10.6)
Gender
 Male 1078 (47.5) 1020 (47.4) 145 (45.7) 62 (48.1)
 Female 1193 (52.5) 1132 (52.6) 172 (54.3) 67 (51.9)
pT stage
 pT3 2007 (88.4) 1931 (89.8) 260 (82.0) 83 (64.3)
 pT4 214 (9.4) 171 (7.9) 56 (17.7) 46 (35.7)
 Unknown 5 (2.2) 50 (2.3) 1 (0.3)
Evaluated lymph nodes
 < 10 1198 (52.8) 1123 (52.2) 194 (61.2) 81 (62.8)
 ≥ 10 946 (41.7) 906 (42.1) 104 (32.8) 44 (34.1)
 Unknown 127 (5.5) 123 (5.7) 19 (6.0) 4 (3.1)
Tumor sidedness
 Right 1251 (55.1) 1188 (55.2) 154 (48.6) 66 (51.2)
 Left 987 (43.4) 934 (43.4) 159 (50.2) 63 (48.8)
 Unknown 33 (1.5) 30 (1.4) 4 (1.3)
Degree of differentiation
 High 145 (6.4) 138 (6.4) 19 (6.0) 10 (7.8)
 Middle 1574 (69.3) 1504 (69.9) 228 (71.9) 76 (58.9)
 Poor 346 (15.2) 314 (14.6) 45 (14.2) 34 (26.4)
 Unknown 205 (9.1) 196 (9.1) 25 (7.9) 9 (7.0)
 Chemotherapy 129 (5.7) NA 25 (7.9) 129 (100.0)
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a biomarker-driven strategy. To explicitly demonstrate 
the impact of treatment on recurrence-free survival and 
colon cancer survival within 5 years, an additional strategy 
was evaluated: (D) none of the patients receive adjuvant 
chemotherapy.
In the 2018 NVMO guideline strategy, adjuvant chemo-
therapy is only considered in stage II colon cancer patients 
with pT4 tumors that are MSS. In the observed adherence to 
the NVMO guideline strategy, adherence was based on treat-
ment allocation according to the most recent NCR data; that 
is 21% of the patients with a pT4 tumor and MSS receive 
chemotherapy and 4% of patients who do not meet these 
high-risk requirements. In the hypothetical biomarker-driven 
strategy, we assumed that all patients with MSS tumors in 
combination with a mutation in BRAF or KRAS receive 
adjuvant chemotherapy.
Results
Characteristics of the patient population
In Table 1, the baseline characteristics for the NCR cohort 
are shown for the whole population (n = 2271), subpopu-
lation 1 (n = 2152) and subpopulation 2 (n = 317). In the 
whole NCR cohort, the majority of patients was aged > 70 
(59.6%), had a pT3 stage tumor (88.4%), less than 10 
lymph nodes examined (52.8%) and a right-sided tumor 
(55.1%). 344 recurrences and 751 deaths were observed. 
Follow-up duration of the patients was at least 36 months, 
with a maximum of 179 months. The median follow-up 
duration was 53 months. There were no missing values 
in the follow-up measurements and age. Only 5.5% of the 
patients had missing values in one of the clinical features 
(pT stage, evaluated lymph nodes and tumor sidedness). 
These missing values were not related to the follow-up 
measurements.
Baseline characteristics for the MATCH cohort, Texas 
cohort and DONOSTIA cohort are shown in Table 2. In 
the MATCH cohort the average age was 69.9 years. The 
Table 2  Patient characteristics 
of the MATCH cohort, Texas 
cohort and Donostia cohort
Data are presented as means (± SD) or numbers (%)
NA not applicable, MSI microsatellite instability independent of status for BRAF and KRAS, MSSdwt 
microsatellite stability without a mutation for BRAF or KRAS; MSSmut microsatellite stability in combina-
tion with a mutation in BRAF or KRAS
Variable Whole population 
(n = 334)
MATCH cohort 
(n = 105)
Texas cohort (n = 133) Donostia 
cohort 
(n = 96)
Age (years) 69.8 (10.6) 69.6 (7.8) 69.6 (11.9) 69.1 (11.9)
Gender
 Male 153 (45.8) 51 (48.6) 72 (54.1) 30 (31.3)
 Female 181 (54.2) 54 (51.4) 61 (45.9) 66 (68.7)
MMR status
 MSI 60 (18.0) 28 (26.7) 9 (6.8) 23 (24.0)
 MSS 219 (65.6) 77 (73.3) 69 (51.9) 73 (76.0)
 Unknown 55 (16.4) 0 (0) 55 (41.4) 0 (0)
BRAF status
 Wild type NA 90 (85.7) NA NA
 Mutation NA 13 (12.9) NA NA
 Unknown NA 2 (1.9) NA NA
KRAS status
 Wild type NA 66 (62.9) NA NA
 Mutation NA 39 (37.1) NA NA
 Unknown NA 0 (0) NA NA
Biomarker subgroup
 MSI 60 (18.0) 28 (26.7) 9 (6.8) 23 (24.0)
 MSSdwt NA 39 (37.1) NA NA
 MSSmut NA 36 (34.3) NA NA
 Unknown 55 (16.4) 2 (1.9) 55 (41.4) 0 (0)
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majority of the patients had a MSSdwt biomarker status 
(37.1%), followed by MSSmut (34.3%) and MSI (26.7%). 
In the Texas cohort, the average age was 69.9 years as 
well. The majority of patients had MSS status (51.9%), 
MSI status was present in 6.8% of the cases, for the 
remaining 41.4%, MMR status was unknown. In the DON-
OSTIA cohort, the average age was 69.1 and the majority 
of patients had MSS status (76.0%). For the three cohorts, 
53 recurrences were observed within 5 years of follow-
up. The median follow-up duration of the patients was 
73 months, with a minimum of 2 months and a maximum 
of 290 months. There were no missing values in the fol-
low-up measurements for all three cohorts.
Estimates for transitions in the model with clinical 
and pathological features only
Transitions DIAG‑90DM, DIAG‑DOC, DIAG‑REC
For the transition DIAG-90DM, we assumed a constant 
transition probability for the first three cycles. For the 
transition DIAG-DOC, a Gompertz distribution was fitted 
to estimate time to DOC (Table 3). Age was included as 
covariate in the survival model. For the transition DIAG-
REC, we used a Gompertz distribution to estimate time 
to recurrence. The included covariates for the transition 
DIAG-REC are the number of evaluated lymph nodes, pT 
stage and tumor sidedness (Table 3). Patients with a miss-
ing value in one of the covariates were excluded from the 
analysis (5.5%).
Transitions REC‑DOC and REC‑DCC.
For transitions REC-DOC and REC-DCC, we first used a 
Log logistic distribution to estimate time to death after a 
recurrence. Age was included as covariate in the survival 
model (Table 3). We subsequently differentiated between 
DOC and DCC, as described above. Tunnel states were used 
to correctly incorporate the time-dependent HR for transi-
tions REC- DOC and REC-DCC in the model.
Subgroups included in the PATTERN model
The transition probabilities are dependent on prognostic fac-
tors, the hazards to transit vary between patients based on 
their clinical and pathological factors. For that reason, 72 
subgroups are distinguished in the practical implementation 
of the cohort model based on; age (50–95) in nine 5-year cat-
egories, number of lymph nodes evaluated (< 10 and ≥ 10), 
pT stage (pT3 and pT4) and tumor sidedness (left and right).
Internal validity of the model with clinical 
and pathological features only
In Online Appendix Figs. 1–3, the ability of the simula-
tion model to reproduce the data is shown for the transi-
tions DIAG-DOC, DIAG-REC and REC-DEATH (REC to 
DOC + DCC) separately. For the transition DIAG-DOC, the 
predicted number of deaths fits well to the observed death 
rate (Online Appendix Fig. 1). For the transition DIAG-
REC, the predicted number of recurrences is less close to 
the data. Especially, the predictions for the subgroups with 
a pT4 profile, for which the sample size was small, devi-
ate from the observed data. However, all Kaplan–Meier 
curves lie within the 95% confidence interval of the para-
metric survival model (Online Appendix Fig. 2). Transitions 
REC-DOC and REC-DCC were estimated in one survival 
model. In contrast to the survival model used for the transi-
tion DIAG-DOC, age was added as a continuous covariate in 
this survival analysis because the small sample sizes of the 
subgroups for age hampered inclusion of age as a categori-
cal variable. For the sum of the transitions REC-DOC and 
REC-DCC, mortality predictions fit in general well with the 
death rate in the dataset. In age categories 85–89 and 90–95, 
the model deviates from the data, probably due to the small 
sample size in these subgroups (Online Appendix Fig. 3).
Results of the Greenwood–D’Agostino–Nam test for 
model calibration are shown in Online Appendix Fig. 4. 
For all three transitions, DIAG-DOC, DIAG-REC and 
REC-DEATH, sufficient model calibration was shown (p 
values of 0.93, 0.16 and 0.29, respectively). In addition, 
C-statistics were 0.74 (0.71–0.78), 0.63 (0.58–0.68) and 
0.64 (0.61–0.68) for the transitions DIAG-DOC, DIAG-REC 
and REC-DEATH, respectively, (Table 3), which indicate 
sufficient to good model discrimination [35]. Finally, the 
model predictions corresponded reasonably well with the 
NCR data used for model development; 73% (66 out of 90) 
of the number of time points for which, in this validation 
exercise, predictions were obtained in the general population 
and in the subgroup populations, were within the 95% CI of 
the data (Online Appendix Table 2).
Addition of biomarker status
The model including clinical and pathological factors was 
extended using three biomarker categories, i.e., MSI, MSS-
dwt and MSSmut. We used a Gompertz distribution to esti-
mate HRs for the 3 subgroups with which we could correct 
the transition DIAG-REC. HRs of 0.25 (0.08; 0.80), 0.88 
(0.08; 11.02) and 1.53 (0.13; 17.75) were estimated for the 
MSI, MSSdwt and MSSmut subgroups, respectively. Param-
eters are shown in Table 3 and the ability of the simulation 
model to reproduce the data is shown in Online Appendix 
Fig. 5.
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Table 3  Parameter estimates specifying transitions in the PATTERN model
90DM 90-day mortality, DOC death other causes, NA not applicable
a Population on which the model is fitted
b Parameters used in the model are the log transformations of the estimated hazard ratios of 0.247, 0.880, 1.528, 0.779, 0.939 respectively for 
MSI, MSSdwt, MSSmut and treatment effect
c Treatment effect for fluoropyrimidine monotherapy compared to no adjuvant chemotherapy
d Treatment effect for FOLFOX compared to Fluoropyrimidine monotherapy
e REC-DOC and REC-DCC were estimated in the same parametric survival model. Transition REC-DCC is calculated as the difference of tran-
sition REC-DOC + REC-DCC and transition REC-DOC
Transition diagnosis to 
90DM (DIAG-90DM)
Transition diagnosis to 
DOC (DIAG-DOC)
Transition diagnosis to 
recurrence (DIAG-REC)
Transition recurrence 
to death (REC-DOC + 
REC-DCC)e
Transition recurrence to 
DOC (REC-DOC)
Subpopulationa Whole NCR population 1 1 2 2
Parametric distribution NA Gompertz Gompertz Log logistic NA
C-statistic NA 0.74 (0.71–0.78) 0.61 (0.56–0.66) 0.64 (0.61–0.68) NA
Probability Coefficient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value Probability
Shape (intercept) NA 0.010 (0.009; 0.012) < 0.01 − 0.016 (− 0.021; − 
0.010)
< 0.01 1.17 (1.06; 1.29) < 0.01 NA
Rate/scale NA 0.000 (0.000; 0.001) 0.02 0.004 (0.003; 0.005) < 0.01 1,390 (397; 4,850) 0.48 NA
Age  NA  NA
 ≤ 54 0.028 (0.004; 0.052) Reference < 0.01 − 3.439 (− 4.363; − 
2.515)
< 0.01 0.000
 55–59 0.028 (0.004; 0.052) 0.632 (− 0,045; 
1,308)
− 3.766 (− 4.778; − 
2.754)
0.001
 60–64 0.032 (0.011; 0.053) 0.591 (− 0.037; 
1,219)
− 4.094 (− 5.194; − 
2.994)
0.001
 65–69 0.032 (0.011; 0.053) 1.039 (0.453; 1.624) − 4.421 (− 5.609; − 
3.233)
0.001
 70–74 0.064 (0.040; 0.087) 1.701 (1.150; 2.252) − 4.749 (− 6.025; − 
3.473)
0.002
 75–79 0.073 (0.050; 0.097) 2.159 (1.617; 2.702) − 5.076 (− 6.440; − 
3.712)
0.003
 80–84 0.114 (0.081; 0.147) 2.823 (2.281; 3.365) − 5.404 (− 6.856; − 
3.952)
0.004
 85–89 0.156 (0.099; 0.213) 3.166 (2.604; 3.729) − 5.731 (− 7.271; − 
4.191)
0.005
 90–95 0.333 (0.178; 0.488) 3.315 (2623; 4.007) − 6.059 (− 7.687; − 
4.431)
0.006
Lymph nodes evalu-
ated (≥ 10 vs < 10)
NA NA NA − 0.519 (− 0.762; − 
0.276)
< 0.01 NA NA NA
pT stage (pT4 vs 
pT3)
NA NA NA 1.081 (0.779; 1.383) < 0.01 NA NA NA
Tumor sidedness (left 
vs right)
NA NA NA 0.505 (0.272; 0.737) <0.01 NA NA NA
Biomarker subgroup NA NA NA NA NA NA
MSI − 1.398b (− 2.571; − 
0.224)
0.23
MSSdwt − 0.128b (− 2.652; 
2.400)
0.45
MSSmut 0.424b (− 2.025; 
2.876)
0.68
Treatment effect NA NA NA − 0.250b,c (− 0.383; 
− 0.118)
< 0.01 NA NA NA
NA NA NA − 0.063b,d (− 0.276; 
0.149)
0.13 NA NA NA
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Addition of treatment effect
We implemented treatment effect in the decision model by 
adjusting the transition DIAG-REC; the shape parameter of 
the Gompertz distribution was multiplied with the previ-
ously estimated HR of 0.73 [24].
External validation of the PATTERN model
The results of the external validation of the PATTERN 
model are shown in Online Appendix Table 2. 72% (13 out 
of 18), 64% (23 out of 36) and 56% (30 out of 54) of the 
model predictions, in the general population and in the sub-
group populations, fitted within the 95% CI of the 2015 NCR 
data at months 12, 24 and 36, respectively. In general, the 
model predictions fitted reasonably well with the 2015 data, 
except for the pT4 subgroup. In this subgroup, at none of 
the time points, the model-predicted recurrence rates fitted 
within the 95% confidence interval. Based on these findings 
and after discussion with clinical experts, the PATTERN 
model was updated to 2015 for the pT4 subgroup. The tran-
sition from recurrence to diagnosis is the only transition in 
the PATTERN model in which pT stage was included as 
covariate. We re-estimated the transition DIAG-REC in the 
NCR 2015 data and compared the betas for pT stage to the 
estimates in the 2002–2008 NCR data. The beta in the 2015 
NCR data was 1.47, which is a factor 1.36 higher compared 
to the 2002–2008 NCR data. The transition from diagno-
sis to recurrence in the PATTERN model was, therefore, 
adjusted by multiplying the original beta for pT stage in 
the PATTERN model by the factor 1.36. After the model 
update, the external validation was repeated and showed that 
83%, 81% and 70% of the model predictions fitted within the 
95% CI of the data at months 12, 24 and 36, respectively. 
Especially, the fit for the pT4 subgroup improved (Online 
Appendix Table 2).
Validation of the treatment effect that was implemented 
in the PATTERN model based on external RCT data,showed 
that overall 94% of the model predictions for recurrence and 
overall survival fitted within the 95% confidence interval of 
the data (Online Appendix Table 4).
Model‑based predictions for the selection strategies
For the selection strategy in which none (strategy D) of the 
patients received adjuvant chemotherapy, the model pre-
dicted 126 recurrences and 89 deaths due to colon cancer 
after 5 years in a cohort of 1000 patients.
For the observed adherence to guideline recommenda-
tions strategy, the model predicted 123 recurrences after 
5 years in a cohort of 1000 patients. For deaths due to colon 
cancer, this figure was 87. In case of 100% adherence to 
the 2018 NVMO guideline recommendations, the model 
predicted 119 recurrences and 83 deaths due to colon can-
cer in a 5-year time horizon. This is a decrease of 3.3% in 
the number of recurrences and a decrease of 4.6% in DCC 
compared to the observed adherence to guideline recom-
mendations strategy. For the hypothetical biomarker-driven 
strategy, 110 recurrences and 77 deaths due colon cancer 
were predicted after 5 years. Compared to observed adher-
ence to guideline recommendations, this is a decrease of 
10.6% in the number of recurrences and a decrease of 11.5% 
in DCC. Model predictions are shown in Fig. 3.
Discussion
In this study, a Markov cohort model was developed for the 
future population-level evaluation of different strategies to 
improve the selection of stage II colon cancer patients for 
adjuvant chemotherapy. The decision model describes the 
influence of pT stage, number of lymph nodes evaluated, 
tumor sidedness, MSS status, BRAF mutation status, and 
KRAS mutation status on relevant outcomes, such as the 
recurrence rate and disease-specific survival. Sufficiently 
adequate internal and external validity of the model was 
demonstrated. To illustrate the application of the model, we 
evaluated the potential health gain that can be achieved with 
100% adherence to the 2018 NVMO guideline recommen-
dations for adjuvant chemotherapy compared to observed 
adherence to these recommendations. A hypothetical bio-
marker selection strategy was evaluated as well. Full adher-
ence to the NVMO guideline and the biomarker strategy 
resulted in a 4.6% and 11.5% decrease, respectively, in colon 
cancer mortality compared to observed adherence to NVMO 
recommendations.
A Markov decision model for the evaluation of adjuvant 
chemotherapy in stage II colon cancer was developed earlier 
by Avayci et al. [36]. These authors used the model to assess 
the cost-effectiveness of adjuvant treatment compared to no 
adjuvant treatment. This study concluded that fluorouracil 
monotherapy was cost-effective; whereas, fluorouracil in 
combination with oxaliplatin was considered as not cost-
effective compared to no treatment. However, this model 
does not distinguish between different patient groups with 
a different prognosis, and is therefore not able to evaluate 
different selection strategies for adjuvant treatment. To our 
knowledge, the PATTERN model is the first model that can 
compare different strategies for selecting high-risk stage II 
colon cancer patients for adjuvant therapy. In addition, the 
PATTERN model is able to perform evaluations for both 
adjuvant treatment with fluoropyrimidine monotherapy and 
fluoropyrimidine combined with oxaliplatin.
To develop the PATTERN model, we assumed that all 
deaths during the first 90 days after diagnosis in the NCR 
dataset were caused by complications of surgery or poor 
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) 
1 3
clinical condition of the patient. The estimated probabili-
ties of 0.029, 0.051 and 0.12 for age categories < 65, 65–74 
and > 74, respectively, were in line with previously reported 
probabilities (0.022, 0.045 and 0.12, respectively) [23]. Fur-
thermore, we assumed that the probability to die from DOC 
was slightly different in the NCR population compared to 
the general population, due to a different selection of indi-
viduals. To illustrate, the factors that increase the risk of 
developing colon cancer are also risk factors for developing 
other chronic diseases, such as cardiovascular diseases [37]. 
Therefore, we used the NCR data to estimate the transitions 
to DOC instead of life tables from the Central Bureau for 
Statistics Netherlands (CBS). As a check, we compared our 
estimates to the CBS, which showed that the probabilities 
to die from DOC as estimated in our data were higher for 
ages lower than 65 and were in line for ages 65–85. After 
age 85, the probability to die due to other causes was lower 
in our dataset compared to the CBS. A reason for the dif-
ference in probability to die from DOC in the population 
aged < 65 could be the different selection of individu-
als compared to the general population. The difference in 
patients aged > 85 might be explained due to the fact that not 
all people aged above the 85 are eligible for the initial sur-
gery due to reduced clinical condition. As we only included 
Fig. 3  Model predictions for 
recurrence-free survival (a) and 
deaths due to colon cancer (b)
 G. Jongeneel et al.
1 3
patients with initial surgery in our analysis, we probably had 
a selection of patients aged above 85 with a better clinical 
condition compared to the general population. In addition, 
we also assumed that patients can only die from colon can-
cer after having a recurrence. That is, patients in our model 
cannot directly transit from diagnosis to DCC. As there may 
be some underreporting of the number of recurrences in the 
NCR data, it is possible that the probability to die from colon 
cancer was also underestimated in the decision model, which 
could result in an underestimation of the impact of adjuvant 
treatment.
In our dataset, 3-year and 5-year disease-free survival 
(DFS) without adjuvant treatment was 0.89 and 0.86, respec-
tively. These probabilities were higher compared to those 
found in the literature. For example, in the QUASAR trial, 
probabilities of 0.81 and 0.76 were found for 3-year and 
5-year DFS, respectively [38]. There are several reasons 
that may explain this difference. First, the populations are 
not completely comparable at baseline. The percentage of 
patients with a pT4 stage in QUASAR was 17.4% compared 
to 9.6% in our data. It should be noted that direct compari-
son of baseline characteristics is hampered due to the fact 
that the QUASAR trial population also included stage III 
patients (8%) and patients with rectal cancer (29%). Sec-
ond, the patient inclusion of the QUASAR trial took place 
in 1994–2003, compared to diagnosis years 2002–2008 in 
the dataset used in the current study. Literature shows that 
quality of diagnosis has improved over the last decades [39]. 
Therefore, it is possible that stage III patients were classi-
fied as stage II patients in QUASAR, which has worsened 
the overall DFS for stage II patients in the QUASAR trial. 
Finally, we cannot exclude the possibility that recurrences 
may have been missed in the Netherlands cancer registry 
(NCR). Overall, the PATTERN model was quantified based 
on Dutch DFS and OS rates. As a consequence, our model 
predictions are only generalizable to countries with similar 
survival rates.
In the survival model that was used to calculate the transi-
tion probabilities for diagnosis to recurrence, the following 
factors were found to be prognostic: pT stage, tumor sided-
ness and number of evaluated lymph nodes. Degree of dif-
ferentiation, despite previously included in the guidelines, 
was not a prognostic factor in our dataset. This finding is in 
line with Snaebjornsson et al. [40] reporting that there is no 
support to take poor differentiation as a high-risk factor in 
stage II colon cancer patients into account when deciding 
on the administration of adjuvant chemotherapy. Despite the 
fact that tumor sidedness is not included in the guidelines 
as a prognostic factor for recurrence, this factor is neverthe-
less included in our survival model because of its strong 
prognostic effect in favor of the right-sided tumors. This is 
in line with a population-based SEER analysis of 33,323 
stage II colon cancer patients which demonstrated that both 
5 year OS and DFS were superior in right-sided compared 
to left-sided colon cancers (HR 0.85, 95% CI 0.81; 0.89 and 
HR 0.75, 95% CI 0.70; 0.80, respectively) [41]. It should 
be noted that this is contradictory to the majority of studies 
regarding the prognostic value of primary tumor location, 
which indicated that patients with a right-sided tumor have 
in general a worse prognosis compared to left-sided tumors 
[42, 43]. Overall, the majority of the prognostic factors 
found in our data were in line with the literature [44].
The external validation, for which the 2015 NCR data 
were used, showed overall good agreement between the 
model predictions and the external data, except for the pT4 
subgroup. The model underestimated the number of recur-
rences in this subgroup. The difference in recurrence rate 
in cohort 2002–2008 and cohort 2015 could potentially be 
explained by the increased awareness of the poorer progno-
sis of pT4 stage II patients compared to pT3 stage II patients, 
which was especially triggered by the published findings of 
the MOSAIC trial in 2004 [4]. It could be that as a result of 
these findings, pT4 patients are currently better monitored 
after diagnosis, leading to earlier detection of recurrences 
and, thus, higher recurrence rates. After discussion with 
clinical experts in the field, we decided to update the beta 
for pT stage, to inform the PATTERN model with the most 
recent information available.
Because there is currently a lack of knowledge in the 
field regarding the most (cost-)effective manner to assign 
treatment in stage II colon cancer patients, it is important to 
combine all the knowledge we have acquired over the past 
decade in a decision model to enable evaluation of selection 
strategies. It is expected that the number of patients with 
stage II colon cancer will increase due to the introduction 
of the Dutch CRC screening program, thereby increasing 
the importance of treating these patients optimally. The 
PATTERN model can address this issue, as has been dem-
onstrated in our simulation of 3 hypothetical strategies for 
100% adherence to the 2018 NVMO guidelines, observed 
adherence to guideline recommendations and a biomarker-
driven strategy.
To adequately interpret the results of these simulations, 
a number of issues require attention. First, treatment het-
erogeneity was not included in the PATTERN model. In a 
previous study, a predictive effect was found for patients 
with a microsatellite instable (MSI) tumor. In addition 
to having a favorable prognosis, it was shown that these 
patients have a certain resistance to fluorouracil-based 
chemotherapy [17]. The predictive treatment effect for 
the MSI subgroup was not taken into account in the PAT-
TERN model, because this patient subgroup is not eligible 
for adjuvant treatment in the current guideline because 
of its favorable prognosis. For the BRAF and KRAS bio-
markers and the other included prognostic features in the 
model, no predictive effect for adjuvant chemotherapy has 
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yet been demonstrated in stage II colon cancer patients. 
It should be noted that the PATTERN model was built 
in a flexible manner, e.g., treatment heterogeneity can be 
implemented when the required data become available. 
Second, it was assumed that the distribution of biomarker 
status was independent of clinical and pathological factors. 
There is no clear evidence in favor or against this assump-
tion. Third, due to limitations in the data, no distinction 
was made in the MSI group for the presence or absence 
of a mutation in BRAF and/or KRAS. In addition, we did 
not correct for heterogeneity between the cohorts used for 
biomarker analysis.
Moreover, it should be noted that we did not aim to con-
duct a full cost-effectiveness analysis to determine the opti-
mal selection strategy for patients with stage II colon cancer. 
Instead, we solely evaluated the impact on health gain of 
a limited number of example strategies on recurrence and 
death to illustrate the application of the model. In this exam-
ple analysis, we did not include adverse effects of adjuvant 
chemotherapy on quality of life and costs. In order to evalu-
ate selection strategies from a health economic perspective, 
the PATTERN model will be further informed with cost data 
and quality adjusted life years (QALYs) data.
To conclude, we presented the development of the 
Personalized Adjuvant TreaTment in EaRly stage coloN 
cancer (PATTERN) model which is, to our knowledge, 
the first model that allows a population-level comparison 
of different personalized strategies for selecting high-risk 
stage II colon cancer patients for adjuvant chemotherapy. 
The model includes clinical and pathological features as 
well as biomarker status for MSS, BRAF and KRAS. This 
model will be used to evaluate the effectiveness and cost-
effectiveness of existing and biomarker-based selection 
strategies to improve treatment allocation in stage II colon 
cancer patients.
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